May 10, 2019 / 5:28 AM / 11 days ago

BRIEF-Novartis Releases New Data On Gilenya MS Drug

May 10 (Reuters) - Novartis AG:

* DATA AT AAN SHOW GILENYA® IS FIRST AND ONLY DISEASE-MODIFYING THERAPY WITH PROVEN SUPERIORITY VERSUS GLATIRAMER ACETATE IN RELAPSING REMITTING MS

* GILENYA SHOWED SIGNIFICANT SUPERIORITY VERSUS GLATIRAMER ACETATE IN OTHER KEY MEASURES OF DISEASE ACTIVITY, SUCH AS BRAIN LESIONS

* THERE WERE MORE DISCONTINUATIONS ON GLATIRAMER ACETATE COMPARED TO GILENYA REINFORCING GILENYA'S ESTABLISHED SAFETY PROFILE Source text for Eikon: Further company coverage: (Berlin Speed Desk)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below